Pharmaceuticals discovered with AI
EFFICIENT DRUG DISCOVERY & DEVELOPMENT
twoXAR Pharmaceuticals is a drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 18 diseases. twoXAR saves years in drug development while generating a 30x hit rate at in vivo efficacy milestones over traditional methods.
WEBINAR SERIES
Part 1: SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem
Part 2: VP Discovery, Aaron Daugherty shares how we collaborate with our partners
Part 3: SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR
LATEST NEWS
LATEST EVENTS
Innovation in Drug Research and Development for Chronic Diseases - Part 1
National Academies of Science, Engineering, and Medicine (Virtual)
February 22, 2021
twoXAR Pharmaceuticals CEO Andrew A. Radin presents in a session on new technologies enabling discovery research.
2021 MIT ILP WuXi Virtual Symposium
MIT ILP (Digital)
January 27, 2021
twoXAR Pharmaceuticals CEO Andrew Radin presents at the MIT Startup Exchange Lightning Talk
(Digital)
January 11-15, 2021
twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.
© 2021 twoXAR, Incorporated | All Rights Reserved